Core Viewpoint - The recent clinical trial results for ASC30, a long-acting GLP-1 receptor agonist developed by the company, indicate its potential as a quarterly administered treatment for weight management in obese patients, showing a 75-day observed half-life [1] Group 1: Company Developments - The company has reported that its ASC30 formulation, designed for weight maintenance, has demonstrated an observed half-life of 75 days in a Phase Ib clinical trial involving obese participants with a BMI of 30 kg/m² or higher [1] - The ASC30 formulation utilizes the company's Ultra-Long-Acting Platform (ULAP) for drug development, highlighting its innovative approach in the pharmaceutical industry [1] - Following a single subcutaneous injection of 100 mg ASC30, the time to reach peak concentration (Cmax) was observed to be 17 days post-administration [1] Group 2: Market Activity - On September 10, shareholders of the company deposited shares into Futu Securities International Hong Kong, with a market value of HKD 1.994 billion, representing 14.11% of the total shares [1]